Gubra stock
GUBRA.COCPHGubra A/S, HealthcareISIN DK0062266474
43Score 43 out of 100, Weak
Price and trend
58 / 100
Price history
−30% in one yearThe chart shows daily closes over 4 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 13% below it.
Since March 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 56).
The price is 43% below its 52-week high. Largest decline in 4 years: 62% (December 2024 to October 2026).
Chart figures for advanced users
- SMA 50$44.94
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$51.55
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)56
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$40.79
- The lowest closing price of the last twelve months.
- Resistance$79.16
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Gubra A/S belongs to the Biotechnology industry (Denmark) and, with a market value of $738.91M, is number 208 of 289 companies in its industry on MEQIRI.
- MEQIRI Score 43 out of 100 (Weak): rank 487 of 702 in Healthcare, median 53.
- Our model puts fair value at $49.05, with the price 8% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings per share growingUp 166% a year since 2020.
- High return on capitalReturn on invested capital 197.1% in fiscal 2025, Biotechnology median −24.3%.
- Growing faster than its industryRevenue up 72.6% a year since 2020, Biotechnology median 19.4%.
Weaknesses
- Loss-makingLoss of $27.02M over the last 12 months.Fundamentals 37
- Negative free cash flowFree cash flow −$117.42M over the last 12 months.Fundamentals 37
- Volatile share priceVolatility 54% a year over the last 12 months.
Its standout strength is stability, while growth and profitability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 41 to 43.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- price far below its 52-week high
What lowers it
- price not overheated over the past year
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $35.03 and expensive above $81.74 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 7.4%. At 8.4% the fair value would be $40.55, at 6.4% it would be $61.55.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Revenue has grown strongly since 2020, at around 73% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 97%, operating 84%, net 64%. Last 12 months: net −67%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 3 Mar 2027in 110 days
- Last reported
- 20 Aug 2026EPS reported −$0.99 (expected −$0.74)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$0.370.0%
- Revenue
- $85.4M0.0%
- Earnings per share
- −$0.530.0%
- Revenue
- $93.8M−0.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Gubra
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 43
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Arbutus BiopharmaABUS $798.37M66
- AlumisALMS $793.44M38
- ArdelyxARDX $784.28M34
- Olema PharmaceuticalsOLMA $760.22M34
- DBV TechnologiesDBV.PA $738.12M40
- Aura BiosciencesAURA $737.34M41
- Attovia TherapeuticsATTO $722.72M44
- OmniAbOABI $722.01M54
ETFs that hold Gubra
Held by 7 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.04% | 0.23% | €321.86M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.03% | 0.40% | €1.5B |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.02% | 0.30% | €3.45B |
Show 4 more
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.10% | €395.74M |
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.01% | 0.30% | €813.64M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.00% | 0.45% | €1.54B |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.00% | 0.17% | €8.84B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = DKK 6.7461)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 2 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.